Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Jeffrey Lancet, MD, of H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, reports results from a Phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.